Pets
“A 2025 peer-reviewed study from São Paulo State University (UNESP), published in the journal Animals, found that both turmeric root (curcumin) and homeopathic turmeric reduced canine bladder cancer cell movement and spread by nearly 76% in 24 hours, outperforming a chemotherapy drug.”
This post lists 4 claims. We checked item 1.
Plain restatementA 2025 paper in Animals, from UNESP, reported that curcumin and a homeopathic Curcuma longa preparation reduced migration of canine urothelial carcinoma cells in a laboratory assay, with reductions of about 75 percent at 24 hours, and that a chemotherapy drug produced a slightly smaller reduction in the same assay.
General information only - not veterinary advice.
The study is real and the numbers are quoted correctly. A 2025 paper in the journal Animals, from São Paulo State University in Brazil, found that curcumin reduced the movement of one line of canine bladder cancer cells by 75.8 percent over 24 hours, a homeopathic turmeric preparation by 74.8 percent, and the chemotherapy drug mitoxantrone by 73.6 percent. The important missing context is that this was done to cells in laboratory dishes, not to dogs, at concentrations applied directly to the cells that oral turmeric does not reach in a dog's bloodstream. The authors themselves write that laboratory studies do not reproduce a living body and that animal studies are needed next, and their own summary describes the chemotherapy drug as strongly cytotoxic, so the "outperforming chemo" framing is not what the paper says. The same paper also found curcumin increased the activity of genes linked to tumour invasion in the canine cells, a result the post leaves out. Because the post attaches a turmeric dosing guide to a cancer headline, it is worth noting that the study positions curcumin only as a possible add-on to conventional treatment, not a replacement for it, and veterinary guidance is that a dog with suspected bladder cancer needs veterinary diagnosis and treatment. General information only, not veterinary advice.
A 2025 [drifted from the evidence:] peer-reviewed study from São Paulo State University (UNESP), published in [drifted from the evidence:] the journal Animals, [drifted from the evidence:] found that [drifted from the evidence:] both turmeric root (curcumin) and homeopathic [drifted from the evidence:] turmeric reduced canine [drifted from the evidence:] bladder cancer cell movement and spread by nearly 76% in 24 hours, [drifted from the evidence:] outperforming a chemotherapy drug.
A 2025 [added by the neutral restatement:] paper in Animals, [added by the neutral restatement:] from UNESP, reported that curcumin and [added by the neutral restatement:] a homeopathic [added by the neutral restatement:] Curcuma longa preparation reduced [added by the neutral restatement:] migration of canine [added by the neutral restatement:] urothelial carcinoma cells in [added by the neutral restatement:] a laboratory assay, with reductions of about 75 percent at 24 hours, [added by the neutral restatement:] and that a chemotherapy drug [added by the neutral restatement:] produced a slightly smaller reduction in the same assay.
Red-tinted words in the claim drifted from the evidence. Green-tinted words are what a neutral restatement needs.
The trace / claim to source
- The study exists, the DOI is correct, it was published in Animals on 29 May 2025, and the lead department is the Department of Veterinary Clinic at São Paulo State University (UNESP), Botucatu.
- The three percentages are quoted accurately from the paper: 75.8 percent for curcumin, 74.8 percent for D6 turmeric, 73.6 percent for mitoxantrone, measured as inhibition of migration in the canine SH cell line after 24 hours in a Transwell assay.
- "Homeopathic turmeric" is a fair description of what was tested. The paper used a 6CH homeopathic dilution of Curcuma longa.
- Curcumin and the homeopathic preparation did reduce viability and migration of canine urothelial carcinoma cells in culture in this study.
- Canine bladder urothelial carcinoma is an aggressive tumour, which is why migration matters as a laboratory readout.
- The result is from cancer cells in plastic dishes, not from dogs. The claim says turmeric reduced "cell movement and spread" in canine bladder cancer, which a reader will hear as an effect in living animals. The authors state that in vitro work does not reproduce the complexity of a living system and call for in vivo studies.
- "Outperforming a chemotherapy drug" is not what the paper reports. The three agents were each tested against their own vehicle controls, and the 75.8 versus 73.6 gap is 2.2 percentage points in one cell line. The paper's own summary says mitoxantrone showed strong cytotoxicity, especially in the canine cells.
- The percentages come from one canine cell line, SH, out of the three canine lines studied. Presenting them as a result for "canine bladder cancer cells" generally overstates the scope.
- "Spread" is not measured. Migration across a membrane in 24 hours is a laboratory proxy; metastasis in a dog was not assessed.
- The concentrations are omitted. The reductions were produced at IC50 concentrations, that is, concentrations that halve cell viability, with curcumin at roughly 12 to 18 micrograms per millilitre applied directly to cells for 72 hours. Published dog data show oral curcumin reaching plasma concentrations in the parts-per-billion range, thousands of times lower, so a kitchen paste does not deliver what the dish received.
- The post omits results from the same paper that cut the other way, including curcumin raising MMP-2 and MMP-9 expression in all canine lines and β1-integrin in two, genes tied to invasion, which the authors note did not align with the migration finding.
- The post pairs the cancer finding with a turmeric dosing guide and paste recipe. Nothing in the study supports a dose for a dog with bladder cancer, and the authors position curcumin as a possible adjuvant to conventional therapy rather than a substitute for it.
- The Cornell item carries the same in-dish-not-in-dog gap, and its two specific numbers were not confirmed.
- Whether the paper reports any statistical test comparing curcumin directly against mitoxantrone. The significance reported in the abstract is against vehicle controls, and no head-to-head superiority test was found in the retrieved text.
- The study's funding statement was not retrieved in full, so independence from commercial turmeric or homeopathy interests is not established either way.
- Whether a homeopathic 6CH dilution contains enough material to act pharmacologically, and by what mechanism, is not resolved by this study and the paper does not settle it.
- The "40 percent apoptosis in 48 hours" and "4.8 times" figures attributed to the Cornell work were not located in the sources retrieved.
- The 20-dog, 42-day turmeric-root extract arthritis study was not identified, so its design and results are unverified.
The cited study is real, the DOI resolves, and the figures quoted in the post appear verbatim in it. Transwell migration assays showed that curcumin, D6 turmeric, and mitoxantrone hydrochloride (at IC50) significantly inhibited SH cell migration after 24 hours: curcumin 75.8 percent, D6 turmeric 74.8 percent, mitoxantrone 73.6 percent. The work is a laboratory cell-culture study. Cytotoxic effects were evaluated in canine (AXA, AXC, SH) and human (T24) urothelial carcinoma cell lines using the MTT assay, and cell viability was assessed using the MTT assay while cell migration was evaluated via the Transwell assay. D6 turmeric was a homeopathic preparation of Curcuma longa at the sixth centesimal Hahnemannian dilution, supplied by a Brazilian compounder and diluted in physiological saline. Cells were treated with curcumin at 12,000 to 18,000 ng/mL, D6 turmeric at 5 to 20 µL/mL, or mitoxantrone at 5 to 40 µM, for 72 hours (curcumin and D6 turmeric) or 24 hours (mitoxantrone). On the comparison with chemotherapy, the paper's own summary runs the other way: curcumin and D6 turmeric reduced cell viability and migration, while mitoxantrone hydrochloride exhibited strong cytotoxicity, especially in canine cells. The molecular results were not uniformly favourable to curcumin: curcumin treatment increased MMP-2 and MMP-9 expression in all canine cell lines, and MMP-2 and MMP-9, key proteases involved in extracellular matrix degradation and invasion, were upregulated in most canine cell lines following curcumin treatment; β1-integrin was also upregulated in two canine lines, and high β1-integrin regulation in cancer cells promotes proliferation, survival, migration and invasion. The authors note this molecular signature did not fully align with the results from the migration assay. The authors state the limits plainly: while in vitro studies provide critical initial evidence, they do not fully replicate the complexity of in vivo systems, and the findings suggest curcumin and D6 turmeric hold promise as complementary therapies for canine urothelial carcinoma, justifying further in vivo investigations. Separately, the broader veterinary review of Curcuma longa reports that clinical evidence remains limited, with most data originating from in vitro studies or pilot studies with small sample sizes, and that low bioavailability of curcumin may limit clinical efficacy. Dog pharmacokinetic work is consistent with that: in one dog plasma study curcumin reached maximum concentrations of 9, 4.5 and 6 parts per billion at 60 minutes in three dogs given traditional capsules, with some samples below the limit of quantitation after a single oral dose of 30 mg/kg.
Complete reasoning
The reply is formatted for pasting into the thread where the claim is circulating.
Ask this case
Answers come only from the case file above; nothing is added.
Is the study real and did it report these percentages?
Yes. A 2025 paper in the journal Animals from Sao Paulo State University (UNESP) reports that curcumin reduced migration of canine urothelial carcinoma cells by 75.8 percent, a homeopathic turmeric preparation by 74.8 percent, and the chemotherapy drug mitoxantrone by 73.6 percent, all after 24 hours in a Transwell assay.
Did the study test this on live dogs with bladder cancer?
No. The study used cancer cells grown in laboratory dishes, not dogs. The authors themselves say lab studies do not reproduce the complexity of a living body and call for animal studies next.
Did turmeric really outperform chemotherapy?
That framing is not supported. The gap between curcumin and mitoxantrone was only 2.2 percentage points in one cell line, and the paper's own summary describes mitoxantrone as showing strong cytotoxicity, especially in canine cells.
Could a dog get this effect by eating turmeric?
The study applied concentrations directly to cells that are far higher than what oral turmeric achieves in a dog's bloodstream. Published dog data show oral curcumin reaching plasma levels thousands of times lower than the concentrations used in this experiment.
Did the study find anything that worked against turmeric's benefit?
Yes. Curcumin treatment increased MMP-2 and MMP-9 expression, genes linked to tumor invasion, in all canine cell lines tested, and the authors note this did not fully align with the migration results. The claim as circulated leaves this out.